What Would Make TMAO a Therapeutic Target?

The evidence now supports more than a correlation but less than a treatment. TMAO is associated with AF in human cohorts, and controlled mouse experiments show that exposure and microbial-pathway inhibition can alter AF-related phenotypes. The next question is practical: what would have to be demonstrated before TMAO could be called a therapeutic target rather than a useful marker or a promising research lead? The answer requires separating several roles that are often compressed into the single word “target.”

A biomarker is not a treatment

A biomarker is a measured feature that helps describe a biological state or forecast an outcome. TMAO may have value in risk stratification if people with higher levels are more likely to experience an AF-related event in a defined setting. The 2026 meta-analysis supports that possibility, but its estimates vary by clinical context and remain largely observational. Risk stratification can inform monitoring or study enrollment without showing that changing the marker will help the person being classified.

A mechanistic marker does something different. It sits close enough to a biological process that measuring it helps explain how disease might develop. The TMAO pathway has this kind of plausibility: dietary substrates can be converted by gut microbes to TMA, the liver can convert TMA to TMAO, and experimental exposure is linked to atrial remodeling, autonomic signaling, and electrical susceptibility in mice. A mechanistic marker can be valuable even if it is not the best predictor and even if changing it does not improve outcomes. Explanation and prediction are related, but they are not interchangeable.

An intervention node is a step in a pathway that can be manipulated. The JCI study identifies microbial TMA lyase activity as one such node in mice. Iodomethylcholine, or IMC, reduced TMA and TMAO in choline-fed mice and delayed or suppressed choline-induced AF. That makes microbial TMA production a candidate intervention point. It does not establish that the node is safe to manipulate in people, that it is the most important node for every patient, or that changing it will improve a clinical endpoint.

A surrogate is a measured response that may stand in for a patient-important outcome. A fall in TMAO after an intervention could show that the pathway was affected. It would be a useful sign that the intervention reached its intended biological target. But it would remain a surrogate unless lower TMAO reliably predicted a meaningful improvement in AF outcomes under the intervention being tested. A biomarker can move in the expected direction while the disease does not, because the disease may have other drivers or because the intervention may create harms that offset the pathway benefit.

A therapeutic target is therefore a stronger claim. It requires an intervention that changes a defined pathway in humans and produces a favorable balance of benefits and harms. For TMAO in AF, that would mean more than demonstrating a lower laboratory value.